Show simple item record

Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study.

dc.contributor.authorVerweij, J
dc.contributor.authorJudson, I
dc.contributor.authorSteward, William P
dc.contributor.authorColeman, R
dc.contributor.authorWoll, Penella J
dc.contributor.authorVan Pottelsberghe, C
dc.contributor.authorVan Glabbeke, Martine M
dc.contributor.authorMouridsen, H
dc.date.accessioned2010-04-22T10:51:29Z
dc.date.available2010-04-22T10:51:29Z
dc.date.issued1994
dc.identifier.citationPhase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study. 1994, 30A (6):842-3 Eur. J. Canceren
dc.identifier.issn0959-8049
dc.identifier.pmid7917546
dc.identifier.doi10.1016/0959-8049(94)90303-4
dc.identifier.urihttp://hdl.handle.net/10541/97145
dc.description.abstractThe EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with intravenous muramyl tripeptide phosphatidylethanolamine (MTP/PE) at a dose of 4 mg once weekly in 20 patients with metastatic soft tissue sarcomas. Responses were not seen in 19 evaluable patients. Toxicity consisted mainly of a mild flu-like syndrome after 62% of drug administrations. It is concluded that MTP/PE at this dose and schedule has no activity in metastatic soft tissue sarcoma.
dc.language.isoenen
dc.subjectSoft Tissue Canceren
dc.subject.meshAcetylmuramyl-Alanyl-Isoglutamine
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntineoplastic Agents
dc.subject.meshDrug Carriers
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLiposomes
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPhosphatidylethanolamines
dc.subject.meshSarcoma
dc.subject.meshSoft Tissue Neoplasms
dc.titlePhase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Rotterdam Cancer Institute, The Netherlands.en
dc.identifier.journalEuropean Journal of Canceren
html.description.abstractThe EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with intravenous muramyl tripeptide phosphatidylethanolamine (MTP/PE) at a dose of 4 mg once weekly in 20 patients with metastatic soft tissue sarcomas. Responses were not seen in 19 evaluable patients. Toxicity consisted mainly of a mild flu-like syndrome after 62% of drug administrations. It is concluded that MTP/PE at this dose and schedule has no activity in metastatic soft tissue sarcoma.


Files in this item

This item appears in the following Collection(s)

Show simple item record